CPC A61K 31/527 (2013.01) [A61K 9/0053 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/555 (2013.01); A61K 31/7048 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07D 487/14 (2013.01)] | 21 Claims |
1. A method of reducing chemotherapy-induced myelosuppression in a human receiving chemotherapy for the treatment of small cell lung cancer comprising administering to the human an effective amount of at least one chemotherapeutic agent and an effective amount of a CDK4/6 inhibitor of the structure
or a pharmaceutically acceptable salt thereof, wherein the CDK4/6 inhibitor is administered 24 hours or less prior to administration of the chemotherapeutic agent.
|